New Therapies

New therapies bring hope after much frustration


 

Collectively representing numerous distinct cancers, gastrointestinal (GI) malignancies are a major health burden worldwide. Despite the development of numerous targeted therapies that have advanced the treatment of several GI cancer types, current treatment options have afforded only modest improvements in survival. Here, we discuss how valuable insights gained from both successes and failures are fostering hope for new therapies.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Survival of pancreatic cancer is better when adjuvant therapy is given in high-volume centers
MDedge Hematology and Oncology
RT for rectal cancer may reduce risk of some other cancers
MDedge Hematology and Oncology
Office visits still common before colonoscopy
MDedge Hematology and Oncology
MAVERICC: Search for predictive biomarkers in first-line colorectal cancer trial goes on
MDedge Hematology and Oncology
Early mortality predicted by age and poor performance status in patients with colon cancer
MDedge Hematology and Oncology
Do we give too much iron?
MDedge Hematology and Oncology
Wide disparity in radiology reads without RECIST
MDedge Hematology and Oncology
Short sleep duration increases risk of death in patients with metastatic colorectal cancer
MDedge Hematology and Oncology
Common medications linked to better survival in pancreatic cancer
MDedge Hematology and Oncology
Neurotoxicity tempers case for oxaliplatin in older adults with colorectal cancer
MDedge Hematology and Oncology